TECENTRIQ Drug Use Surveillance (ENKL)

TECENTRIQ Drug Use Surveillance (ENKL) - TECENTRIQ Drug Use Surveillance (ENKL)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059928

Enrollment

Registered

2025-12-01

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ENKL

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Enrolled Cases: All pediatric patients with relapsed or refractory ENKL who plan to use this drug from the date of addition of indication to relapsed or refractory ENKL (September 19, 2025) to the end of the enrollment period

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Response rate based on the judgment of the attending physician	—

Secondary

Measure	Time frame
Percentage of adverse reaction cases (by MedDRA PT, severity, and grade)	—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd Safety Science 2 Department

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results